

AP

1645
76

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Dario NERI et al.

Serial No.: 09/300,425

Group Art Unit: 1645

Filed: 28 April 1999

Examiner: Virginia A. PORTNER

For: SPECIFIC BINDING MOLECULES FOR THE ED-B DOMAIN OF FIBRONECTIN

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

- ☐ Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:
- ☐ within three months of the filing date of a national application other than a CPA under § 1.53(d);
- ☐ within three months of the actual filing date of the national phase of a PCT application; OR
- ☐ before the mailing of a first substantive office action (including after filing of an RCE).
- ☒ Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:

a final rejection under 37 C.F.R. 1.113;

termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
OR

a notice of allowance under 37 C.F.R. § 1.311; and

is accompanied by:

- ☐ the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
 - ☒ a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
- ☐ Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:
- ☐ a final action under 37 C.F.R. § 1.113;
 - ☐ termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR
 - ☐ a notice of allowance under 37 C.F.R. § 1.311;

AND is filed on or before payment of the issue fee; AND is accompanied by:

- ☐ the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).

Statements Under 37 C.F.R. 1.97(e)

- ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.

Cited Materials

- ☒ Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No. 09/075,338, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).
- ☐ Copies of materials listed but not attached were cited in an international search report dated _____.
- ☐ Copies of the materials listed are attached (except for the foregoing).

Non-English Language References

☐ An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).

☐ A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:

X = document of particular relevance when it is taken alone

Y = document of particular relevance when it is combined with another such document

A = document defining the general state of the art

O = non-written disclosure

P = intercalated document

T = document cited to understand the theory or principle underlying the invention

E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date

D = cited in the application

L = cited for another reason

& = publication of member of same patent family

☐ Translation of other relevant information on foreign search report

[insert necessary translation here]

Other Information


Payment of Fees Due (If Any):

☒ A check for \$180.00 covering the fee identified above is attached.

☐ Please charge to Deposit Account No. 13-3402 \$_____ for the fee identified above.

☒ The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



Anthony J. Zelano, Reg. No. 27,969
Attorney for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: ELLIS-0002-P01

Date: February 7, 2005

AJZ:at

K:\Ellis\2 p1\Information Disclosure Statement.doc

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	09/300,425
Filing Date	28 April 1999
First Named Inventor	Dario NERI et al.
Group Art Unit	1645
Examiner Name	Virginia A. PORTNER
Attorney Docket Number	ELLIS-0002-P01

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	1	5,734,025		KOMAI et al.	03-1998
	2	5,849,701		ROBERTS et al.	12-1998
	3	5,747,452		RUOSLAHTI et al.	05-1998
	4	5,837,813		RUOSLAHTI et al.	11-1998
	5	5,523,229		FEINBERG et al.	06-1996
	6	6,696,245		WINTER et al.	02-2004
	7	5,710,134		BOSSLET et al.	01-1998
	8	6,140,470		GAREN et al.	10-2000
	9	5,243,029		MATUSUURA et al.	09-07-1993
	10	5,817,776		GOODMAN et al.	10-06-1998
	11	5,843,156		SLEPIAN et al.	12-01-1998
	12	5,976,535		FRITZBERG et al.	11-02-1999
	13	6,036,955		THORPE et al.	03-14-2000
	14	6,051,230		THORPE et al.	04-18-2000

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†*
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	15	WO	9958570 /		Dario NERI et al.	10-18-1999		
	16	WO	0162800 /		Dario NERI et al.	08-30-2001		
	17	WO	96/23816 /		CREIGHTON et al.	08-08-1996		
	18	EP	0760679		Dario NERI et al.	03-12-1997		
	19	EP	0211047 /		LAI et al.	02-25-1987		
	20	EP	0371998 /		ROBINSON et al.	06-13-1990		
	21	EP	0396612 /		LEI et al.	11-14-1990		
	22	EP	0550400 /		ROBINSON et al.	07-07-1993		
	23	EP	0731167 /		ROBINSON et al.	09-11-1996		

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer.

The PTO did not receive the following
listed item(s) cite # 18



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)


Sheet 2 of 4

Complete if Known

Application Number	09/300,425
Filing Date	28 April 1999
First Named Inventor	Dario NERI et al.
Group Art Unit	1645
Examiner Name	Virginia A. PORTNER
Attorney Docket Number	ELLIS-0002-P01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	24	TOMOHIKO FUKUDA ET AL., "Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro," Cancer Research, 1 October 2002, pages 5603-5610, vol. 62. ✓	
	25	ANDREW GRIFFITHS ET AL., "Isolation of high affinity human antibodies directly from large synthetic repertoires," The EMBO Journal, 1994, pages 3245-3260, vol. 13, no. 14. ✓	
	26	Dario NERI et al., "Affinity reagents against tumour-associated extracellular molecules and newforming vessels," Advanced Drug Delivery Reviews, 6 April 1998, pages 43-52, vol. 31, no. 1-2, XP002124780, pages 46, right-hand column, page 49, left-hand column. ✓	
	27	PINI, A., et al., "Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel," Journal of Biological Chemistry, August 21, 1998, pages 21769-21776, Vol. 273, no. 34, XP002124781. ✓	
	28	VITI F. ET AL., "Increased Binding Affinity and Valence of Recombinant Antibody Fragments Lead to Improved Targeting of Tumoral Angiogenesis," Cancer Research, 15 January 1999, pp. 347-352, vol. 59, no. 2, XP002124782, the whole document. ✓	
	29	TARLI L ET AL., "A high-affinity human antibody that targets tumoral blood vessels," Blood, 1 Jul 1999, pages 192-8, vol. 94, no. 1, XP002124784. ✓	
	30	M. ZALUTSKY ET AL., "Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localization," Proceedings of the National Academy of Sciences in the U.S.A., September 1989, vol. 86, no. 18, pages 7149-7153, XP002172060, Washington DC, USA, abstract. ✓	
	31	S. LINDEGREN ET AL., "Chloramine-T in high-specific-activity radioiodination of antibodies using N-succinimidyl-3-(trimehtylstannyl)benzoate as an intermediate," Nuclear Medicine and Biology, October 1998, pages 659-665, vol. 25, no. 7, XP004149436, Oxford, GB, abstract. ✓	
	32	M. BIRCHLER ET AL., "Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment," Nature Biotechnology, October 1999, pages 984-988, vol. 17, no. 10, XP002172061, New York, NY, USA, the whole document. ✓	
	33	Carnemolla, et al., "The Inclusion of the Type III Repeat ED-B in the Fibronectin Molecule Generates Conformational Changes That Unmask a Cryptic Sequence" The Journal of Biological Chemistry, (1992) Vol. 267, No. 34, pp. 24689-24692. ✓	
	34	DARIO NERI ET AL., "Antibodies from phage display libraries as immunochemical reagents," Methods in Molecular Biology, Immunochemical protocols, 2nd ed., pp. 475-500, vol. 80. ✓	
	35	BIRCHLER ET AL., "Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers," Journal of Immunological Methods, 1999, pages 239-248, vol. 231. ✓	
	36	FREDRIK NILSSON ET AL., "The use of phage display for the development of tumour targeting agents," Advanced Drug Delivery Reviews, 2000, pages 165-196, vol. 43. ✓	
	37	FREDRIK NILSSON ET AL., "Targeted Delivery of Tissue Factor to the ED-B Domain of Fibronectin, a Marker of Angiogenesis, Mediates the Infarction of Solid Tumors in Mice," Cancer Research, 15 January 2001, pages 711-716, vol. 61. ✓	
	38	HALIN ET AL., "Antibody-based targeting of Angiogenesis," Critical Reviews in Therapeutic Drug Carriers Systems, 2001, pages 299-339, vol. 28, no. 3. ✓	



39	LEONARDO GIOVANNONI ET AL., "Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening," <i>Nucleic Acids Research</i> , 2001, vol. 9, no. 5, e27.	
40	SALVATORE DEMARTI ET AL., "Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin," <i>European Journal of Nuclear Medicine</i> , April 2001, short communication, vol. 28, no. 4.	
41	BARBARA CARNEMOLLA ET AL., "Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix," <i>Hemostasis, Thrombosis, and Vascular Biology, Blood</i> , 1 March 2002, pages 1659-1665, vol. 99, no. 5.	
42	HALIN ET AL., "Enhancement of the antitumor properties of interleukin-12 by its targeted delivery to the tumor blood vessel extracellular matrix," <i>Nature Biotechnology</i> , March 2002, pages 264-269, vol. 20.	
43	C MARTY ET AL., "Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes," <i>British Journal of Cancer</i> , 2002, pages 106-112, vol. 87, Cancer Research UK.	
44	SAMU MELKKO ET AL., "An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance," <i>Int. J. Radiation Oncology Biol. Phys.</i> , 2002, pages 1485-1490, vol. 54, no. 5.	
45	PATRIZIA CASTELLANI ET AL., "Differentiation between High- and Low-Grade Astrocytoma Using a Human Recombinant Antibody to the Extra Domain-B of Fibronectin," <i>American Journal of Pathology</i> , November 2002, 1695-1700, vol. 161, no. 5, American Society for Investigative Pathology.	
46	L BORSI ET AL., "Selective Targeting of Tumoral Vasculature: Comparison of Different Formats of an Antibody (L19) to the ED-B Domain of fibronectin," <i>Int. J. Cancer</i> , 2002, pages 75-85, vol. 102.	
47	M SANTIMARIA ET AL., "Immunoscintigraphic Detection of the ED-B Domain of Fibronectin, a Marker of Angiogenesis, in Patients with Cancer," <i>Clinical Cancer Research</i> , February 2003, pages 571-579, vol. 9.	
48	J SCHEUERMANN ET AL., "Discovery and investigation of lead compounds as binders to the extra-domain B of the angiogenesis marker, fibronectin," <i>Drug Development Research</i> , 2003, pages 268-282, vol. 58.	
49	HALIN ET AL., "Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor α ," <i>Cancer Research</i> , 15 June 2003, pages 3202-3210, vol. 63.	
50	L BORSI ET AL., "Selective targeted delivery of TNF α to tumor blood vessels," <i>Blood First Edition Paper</i> , prepublished online 21 August 2003, American Society of Hematology, DOI 10.1182/blood-2003-04-1039.	
51	M NICOLO ET AL., "Expression of Extradomain-B-containing Fibronectin in Subretinal Choroidal Neovascular Membranes," 2003, Elsevier Science Inc.	
52	F VITI ET AL., "Recombinant antibodies for the selective targeting of tumor neovasculature," <i>Current Opinion in Drug Discovery & Development</i> , 2002, pages 204-213, vol. 5, no. 2.	
53	F VITI ET AL., "Phage display libraries as a source of tumour-targeting agents," <i>Chimia</i> , 2001, pages 206-211, vol. 55, ISSN 0009-4293, The Academic Polymer Scene in Switzerland.	
54	D NERI ET AL., Edited by P. RIVA, "New Approaches to Tumour Targeting," <i>Cancer Radioimmunotherapy: Present and Future</i> , Nuclear Medicine Department, Hospital "M. Bufalini," Cesena, Italy, Harwood academic publishers.	
55	M BIRCHLER ET AL., "Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors," <i>Laryngoscope</i> , July 2003, pages 1231-1237, vol. 113.	
56	ALAN L. EPSTEIN, et al., "Identification of a Monoclonal Antibody, TV-1, Directed against the Basement Membrane of Tumor Vessels, and Its Use to Enhance the Delivery of Macromolecules to Tumors after Conjugation with Interleukin 2," <i>Cancer Research</i> 55, pages 2673-2680, June 15, 1995.	
57	J PETERS ET AL., "Fibronectin Isoform Distribution in the Mouse: II. Differential Distribution of the Alternatively Spliced EIIIB, EIIIA, AND V Segments in the Adult Mouse," <i>Cell Adhesion and Communication</i> , 1996, pages 127-148, vol. 4, no. 2.	
58	Chevalier, X., et al., "Increased expression of Ed-B-Containing fibronectin (an embryonic isoform of fibronectin) in human osteoarthritic cartilage," <i>British Journal of Rheumatology</i> , Vol. 35(5), pages 407-415, (abstract only)	
59	Chevalier, X., et al., "Presence of ED-A containing Fibronectin in human articular cartilage from patients with osteoarthritis and rheumatoid arthritis," <i>Journal of Rheumatology</i> , Vol. 23(6), pages 1022-1030, June 1996	
60	Moyano, JV, et al., "Fibronectin type III5 repeat contains a novel cell adhesion sequence, KLDAPT, which binds activated $\alpha 4 \beta 1$ and $\alpha 4 \beta 7$ integrins," <i>Journal of Biological Chemistry</i> , Oct. 3, 1997, Vol. 272(40), pages 24832-24836	

